Our study demonstrates the potential to augment the prognostic stratification of patients with ER+HER2– BC and TNBC by computational assessment of spatial aspects of tumor proliferation and tissue immune response based on DIA data obtained from digitized Ki67 and CD8 IHC slides. Here, ERBB2 is linked to breast cancer.